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A B S T R A C T
Background
Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural distur-
bances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some
evidence that early intervention services can help, and diagnostic techniques that could contribute to early intervention may offer
clinical utility in these situations. The index test being evaluated in this review is the structural magnetic resonance imaging (MRI)
analysis technique known as voxel-basedmorphometry (VBM) that estimates the distribution of grey matter tissue volume across several
brain regions. This review is an exploratory examination of the diagnostic ‘potential’ of VBM for use as an additional tool in the clinical
examination of patients with first episode psychosis to establish whether an individual will progress on to developing schizophrenia as
opposed to other types of psychosis.
Objectives
To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants
who have received a clinical diagnosis of first episode psychosis.
Search methods
In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP.
Selection criteria
We included retrospective and prospective studies that consecutively or randomly selected adolescent and adult participants (< 45
years) with a first episode of psychosis; and that evaluated the diagnostic accuracy of VBM for differentiating schizophrenia from other
psychoses compared with a clinical diagnosis made by a qualified mental health professional, with or without the use of standard
operational criteria or symptom checklists. We excluded studies in children, and in adult participants with organic brain disorders or
who were at high risk for schizophrenia, such as people with a genetic predisposition.
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Data collection and analysis
Two review authors screened all references for inclusion. We assessed the quality of studies using the QUADAS-2 instrument. Due to
a lack of data, we were not able to extract 2 x 2 data tables for each study nor undertake any meta-analysis.
Main results
We included four studies with a total of 275 participants with first episode psychosis. VBM was not used to diagnose schizophrenia
in any of the studies, instead VBM was used to quantify the magnitude of differences in grey matter volume. Therefore, none of the
included studies reported data that could be used in the analysis, and we summarised the findings narratively for each study.
Authors’ conclusions
There is no evidence to currently support diagnosing schizophrenia (as opposed to other psychotic disorders) using the pattern of
brain changes seen in VBM studies in patients with first episode psychosis. VBM has the potential to discriminate between diagnostic
categories but the methods to do this reliably are currently in evolution. In addition, the lack of applicability of the use of VBM to
clinical practice in the studies to date limits the usefulness of VBM as a diagnostic aid to differentiate schizophrenia from other types
of psychotic presentations in people with first episode of psychosis.
P L A I N L A N G U A G E S U M M A R Y
Brain imaging for diagnosing schizophrenia in people with first episode psychosis
Background
Schizophrenia is a psychiatric disorder which involves psychotic symptoms such as distortions in thought and perception, blunted
affect, and behavioural disturbances. It is important for patients who have a first episode of psychosis to be correctly diagnosed as soon
as possible. The earlier schizophrenia is diagnosed the better the treatment outcome. However, other diseases sometimes have similar
psychotic symptoms as schizophrenia, for example bipolar disorder. This review looks at how accurate a type of brain imaging technique
called voxel-based morphology (VBM) is at diagnosing schizophrenia in people who have a first episode of psychosis. VBM is used to
measure differences in the structure of the brain in people with different types of psychosis. These differences could be used to make a
diagnosis.
Study characteristics
The evidence is current to December 2013. We found four studies that used VBM in 275 adolescents and adults with first episode
psychosis. One study recruited participants from a hospital, one from an outpatient clinic and one from inpatient and outpatient
psychiatric services, and the fourth study did not report setting. Participants’ mean age ranged from 18.6 to 27.1 years. Only two
studies reported on participants’ gender and included both males and females.
Quality of the evidence
Study quality was found to be fairly good overall. In some instances it was unclear, mainly due to three of the studies that did not
sufficiently describe method of VBM image processing. We were concerned about all of the studies’ applicability because VBM was
not used to diagnose schizophrenia in any of the studies, instead VBM was used to characterise differences in the brain’s grey matter.
Key results
The four studies we identified used VBM on adolescents and adults with first episode psychosis, but VBM was used to describe brain
structure and not to make a diagnosis. There is no evidence to support the use of VBM to diagnose schizophrenia in patients with first
episode psychosis.
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B A C K G R O U N D
Target condition being diagnosed
Schizophrenia is a psychiatric disorder described in the Diagnos-
tic and Statistical Manual of Mental Disorders, 5th ed. (DSM-
5) (APA 2013) and the International Statistical Classification of
Diseases and Related Health Problems, 10th revision (ICD-10)
(WHO 1992), and is characterised by the presence of delusions,
hallucinations, disorganised speech and behaviour, and negative
symptoms. To warrant a diagnosis, an individual must have been
exhibiting at least two of the preceding symptoms for six months,
with at least one symptom active during the prior month (APA
2013). Schizophrenia can occur as a single episode of illness, al-
though the majority of sufferers have remissions and relapses, and
for many sufferers the condition becomes chronic and disabling
(Bustillo 2001). Themost effectivemethodof treatment is antipsy-
chotic medication (first- and second-generation antipsychotics),
which has been shown to reduce the risk of relapse and psychotic
symptoms (Kane 2001). However, these medications produce var-
ious side effects (Kane 2001), so low doses, used in as timely a fash-
ion as possible, are indicated. It has been suggested that the longer
psychosis goes unnoticed and untreated, themore severe the reper-
cussions for relapse and recovery (Bottlender 2003; Malla 2005).
There is some evidence to suggest that early intervention for people
with schizophrenia can be beneficial, helping avoid or postpone
damaging relapses and the need for prolonged use of medications
(Marshall 2011). Thus, accurate diagnostic techniques that could
contribute to early intervention may offer clinical utility in these
situations.
Index test(s)
The index test being evaluated in this review is the structural mag-
netic resonance imaging (MRI) analysis technique known as voxel-
basedmorphometry (VBM) that estimates the distribution of grey
matter tissue volume across several brain regions (Good 2001). As
a ‘whole brain’-based method, VBM has often been used to locate
the brain regions showing maximal tissue reduction in one group
relative to the other (Mechelli 2005; McCarley 1999; Whitwell
2009). It is believed that VBM provides a means of measuring
brain abnormalities in first episode psychosis that could poten-
tially be used in the differential diagnosis of schizophrenia and
other psychotic disorders (McCarley 1999; Shenton 2001).
Radiological inspection of brain scans is not currently used as a di-
agnostic tool in schizophrenia, and there is also a lack of evidence to
support the routine use of standard radiological reporting of MRI
to detect clinically relevant structural abnormalities in first episode
psychosis (NICE 2008; Sommer 2013). Despite this, it is impor-
tant to evaluate whether specific techniques, such as VBM, could
be applied in order to help differentiate first episode schizophrenia
fromother forms of psychosis. At present there are no tools that are
available in routine practice to complement the prolonged period
of clinical observation required to diagnose schizophrenia. Neu-
roimaging has been highlighted as a promising tool in this regard,
due to its non-invasive nature and consistency of findings from re-
search studies investigating the pathophysiology of schizophrenia
(Gur 2007).
VBM studies have been primarily employed to detect the anatom-
ical patterns of group differences in grey matter volume that are
characteristic of schizophrenia compared to non-schizophrenia
groups (healthy controls or other psychotic disorders). VBM stud-
ies generally report group differences in terms of effect size metrics
such as T statistics rather than absolute volume measures, as the
measurement is based on aprobabilistic estimate of image intensity
and not the actual volume of brain tissue. Meta-analyses estimat-
ing the likelihood of anatomical distribution of VBM changes in
schizophrenia compared to controls implicate several brain regions
such as the fronto-insular cortex, anterior cingulate cortex, supe-
rior temporal gyrus, thalamus, hippocampus and parahippocam-
pal region (Chan 2011; Ellison-Wright 2008; Glahn 2008;Honea
2005).
An appraisal of the current VBM meta-analytic literature in
schizophrenia highlights several important issues. Firstly, most
VBM studies are conducted in patients with chronic, established
illness. Secondly, in most cases the control groups include healthy
individuals rather than a clinically ill patients group with psy-
chosis other than schizophrenia. Thirdly, most studies have been
conducted on patients exposed to various doses and length of an-
tipsychotic medications, which can have confounding effects on
the findings. Finally, the identification (a ‘positive’ result) of grey
matter changes in VBM when comparing two groups is generally
based on diverse statistical approaches that vary in terms of their
choice of multiple-test correction, number of voxels (spatial ex-
tent or cluster size) and the effect size (T values or peak height
threshold) for including voxels in a reported finding (Henley 2010;
Whitwell 2009). As a result, there are currently no generally ac-
cepted standards for VBM positivity threshold.
In practice, most studies have considered regional grey matter
changes to be significant if the group differences survive the test
of a pre-specified statistical threshold on parametric T maps (or z
score maps) of the brain. Grey matter changes that are picked up
by VBM technique occur in a wide variety of disorders including
other psychiatric and neurological disorders (Goodkind 2015). As
a result, a diagnostic VBM test result should be based on both the
spatial distribution and the extent of changes that define the pat-
tern of abnormalities in schizophrenia. While no distinct patterns
of grey matter changes have shown to be specific to schizophrenia
to date, a reduction in grey matter in the aforementioned brain re-
gions appears to be a consistent and robust finding that is reliably
demonstrated in schizophrenia. In addition, statistical discrimi-
natory approaches aimed at the detection of diagnostic patterns
to estimate the test accuracy of VBM are also becoming increas-
3Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ingly popular, including the use of machine-learning algorithms
to study the pattern of multivariate changes that best discriminate
between two groups and allow test accuracy to be quantified using
permutation approaches (Schnack 2014).
Clinical pathway
Schizophrenia typically develops in adolescence or early adult-
hood, though several premorbid indicators are associated with the
onset of the illness. At present, a clinical diagnosis is considered
only after a full-blown psychotic episode. For someone with psy-
chotic symptoms, if it is the first time they have experienced delu-
sions or hallucinations, they would be considered to have ’first
episode psychosis’. Patients typically present to primary care or
emergency services from where they are referred to ’Early Inter-
vention Teams’ in the UK and similar secondary care services else-
where. At present, diagnosis of schizophrenia is made only after
several months of longitudinal observation using widely accepted
nosological criteria (ICD or DSM). Once someone has received
such a diagnosis this has major treatment, psychological and social
implications. People may be treated with antipsychotic medica-
tions, which carry risk of serious adverse effects, may be treated
for long periods, and a person’s life course may alter. A diagnosis
of schizophrenia is thought to be useful - swiftly communicating
much information about the person’s condition - but it carries
with it a stigma.
While radiological investigations are not currently used in the
diagnosis of schizophrenia, it is envisaged that a diagnostic tool
(such as VBM) will be available either at the primary or secondary
care setting to reduce the lead-time for diagnosis, thus reducing
the duration of the current prolonged assessment pathway (Gur
2007; Lawrie 2011).
Rationale
It has long been thought that abnormalities in the brain might be
involved in the aetiology of schizophrenia. To date, brain imag-
ing studies have found grey matter deficits, ventricular enlarge-
ment, and reduced overall brain volume in first episode psychosis
(Fannon 2000). However, as brain abnormalities in schizophre-
nia have been found to be small and indistinct, it is important
to use techniques that might be able to detect these (McCarley
1999). Therefore, this review will focus on a fine-tuned mea-
surement of brain structure known as voxel-based morphometry
(VBM), which examines the whole brain and can detect small re-
gional differences in grey or white matter concentration and vol-
ume (Mechelli 2005).
This review is an exploratory examination of the diagnostic ‘po-
tential’ of VBM for use as an additional tool in the clinical exami-
nation of patients with first episode psychosis to establish whether
an individual has schizophrenia as opposed to other types of psy-
chosis, specifically bipolar disorder and drug-induced psychosis. It
has been suggested that the longer psychosis goes unnoticed and
untreated, the more severe the repercussions for relapse and re-
covery (Bottlender 2003; Malla 2005). There is some evidence to
suggest that early intervention for people with schizophrenia can
be beneficial, helping avoid or postpone damaging relapses and
the need for prolonged use of medications (Marshall 2011). Thus,
accurate diagnostic techniques that could contribute to early inter-
vention may offer clinical utility in these situations. For instance,
first episode psychosis in bipolar disorder can be prone to initially
receiving a misdiagnosis of schizophrenia which is only resolved at
a later stage (Gonzalez-Pinto 1998). Furthermore, a first episode
of psychosis that results from toxic effect substances may mimic
psychosis due to schizophrenia. Thus, an objective test to identify
schizophrenia, will be most useful in first episode psychosis.
In this review we have not included VBM studies that focus on
individuals who do not exhibit frank psychosis but are deemed
to be at a high risk for later development of schizophrenia. This
so called ’at-risk population’ is highly heterogenous, comprised of
genetically high-risk (having first degree relatives with schizophre-
nia), clinically high-risk (experiencing variously defined prodro-
mal symptoms) and both genetic and clinical high-risk groups
(Fusar-Poli 2013). To diagnose later development of schizophre-
nia, these samples must be followed up for long periods to observe
transition to psychosis (36% conversion to psychosis in three years
(Fusar-Poli 2012). Owing to the poor conversion rates, lack of
defined prevention strategies and the heterogeneity of identifica-
tion criteria, the clinical utility and predictive value of developing
a diagnostic test for schizophrenia for this sample is questionable
(Lawrie 2011). Consequently, we have not considered VBM stud-
ies in high-risk samples in the current review.
This review is part of a series of Cochrane reviews using the
same methodology to assess the diagnostic accuracy of tests for
schizophrenia, such as first-rank symptoms (Soares-Weiser 2013)
and the Operational Criteria Checklist for Psychotic Illness and
Affective Illness (OPCRIT+) (Bergman 2014).
O B J E C T I V E S
To determine the test accuracy of voxel-based morphometry
(VBM) in diagnosis of schizophrenia compared with other types
of psychosis in adults and adolescents who have experienced a first
episode psychosis.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included cross-sectional and delayed verification (cohort) ac-
curacy studies that evaluated the diagnostic accuracy of VBM for
differentiating schizophrenia from other psychoses in participants
with first episode psychosis. We included both retrospective and
prospective studies that consecutively or randomly selected partic-
ipants. We excluded case-control studies that compared confirmed
target disease-positive individuals with healthy controls. Studies
were included irrespective of publication status and language.
Participants
We included studies with adolescents and adults presenting with
symptoms thought indicative of first episode psychosis, which are
likely to include psychotic symptoms such as, hallucinations, delu-
sions, disordered thinking, and speech. We did not exclude on
grounds of co-morbidities. We excluded studies involving partici-
pants with organic brain disorders, such as that triggered by an ex-
istent physical disease or alcohol and drug abuse.We also excluded
studies that included participants with childhood psychosis, with
early onset in childhood, as well as late onset psychosis, with onset
at or above the age of 45 (DSM-III), and studies with participants
at high risk for schizophrenia. In addition, we collected data on
whether participants were given some specific prior test or treat-
ment before entering the study.
Index tests
The index test is voxel-based morphometry (VBM), which is a
structural magnetic resonance imaging (MRI) technique that is
able to identify neuroanatomical differences between brains by
making voxel-wise comparisons (Mechelli 2005, McCarley 1999,
Whitwell 2009). We specifically investigated grey matter deficits
in individuals presenting with first episode psychosis. There is no
accepted threshold for a diagnosis of schizophrenia, as this test
is at an early stage of development and interpretation is likely to
be subjective and qualitative. Therefore, in line with diagnostic
test accuracy review protocols of other similar neuroimaging tech-
niques (for example, Vacante 2013), we used the criteria which
were applied in each included primary study to classify partici-
pants as either VBM positive or VBM negative.
VBM tests can be applied in different ways (see Investigations of
heterogeneity), and we noted how each study employed VBM.
The most important aspect of the index test evaluated here is the
application of VBM technique to the entire brain in a voxel-wise
fashion, rather than selecting regions-of-interest. As the pre-test
probability, image processing methodology, statistical approaches
and posterior probability of group differences are likely to be very
different when selected regions are studied as opposed to a whole
brain voxel-wise search, we defined the fidelity of VBM on the
basis of whole brain voxel-wise application.
The quality ofVBManalysis ofMRIdata canmainly be affected by
two sources of variation, imagemovement artefacts anduniformity
of image pre-processing (Ridgway 2008). As a result, we planned to
explore these sources of variation in Investigations of heterogeneity
and considered them in the Assessment of methodological quality.
Target conditions
All types of schizophrenia disorder, regardless of descriptive sub-
category (e.g. paranoid, disorganised, catatonic, undifferentiated
and residual). We included studies that reported results combined
for diagnoses related to schizophrenia (e.g. schizoaffective and
schizophreniform disorder) in which data could not be separated,
but considered these studies a potential source of heterogeneity.
Reference standards
The reference standard is diagnosis through history and clinical
examination collected by a qualified professional (e.g. psychiatrist,
nurse or social worker), which may or may not involve the use of
operational criteria or checklists of symptoms such as International
Statistical Classification of Diseases (ICD-9 or ICD-10; WHO
1992) or Diagnostic and Statistical Manual of Mental Disorder
(DSM-III, DSM-IV or DSM-5; APA 2013). This type of clinical
diagnosis requires the presence of symptoms for at least six months
to confirm the diagnosis. We considered differences in reference
standard a potential source of heterogeneity.
Search methods for identification of studies
Electronic searches
We conducted searches in MEDLINE, EMBASE, and PsycInfo
using OvidSP in May 2012 and December 2013, see Appendix 1
for details of the search strategies.
We did not apply any restrictions based on language or type of
document in the search. We used the multipurpose search com-
mand for the OvidSP interface (.tw.) to search both database ab-
stract and title fields. To capture variations in suffix endings, the
truncation operator ‘$’ was used.
Searching other resources
We identified additional references by manually searching the ref-
erence lists of included studies.
Data collection and analysis
We followed the guidelines provided in the Cochrane Diagnostic
Reviewer’s Handbook (DTA Handbook 2013).
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Selection of studies
Atoosa Khodabakhsh (AK) and Nicola Mayaan (NM) indepen-
dently screened all titles and abstracts for eligibility. Full papers of
potentially relevant studies were retrieved, as well as review articles,
if they were relevant, for manual reference search. AK and NM
independently reviewed the full papers for eligibility according to
the inclusion criteria detailed above. We included abstracts in the
absence of a full publication if sufficient data were provided for
analysis. Any disagreements were resolved by discussion between
AK and NM and all decisions documented. Lena Palaniyappan
(LP) made a final decision regarding inclusion or exclusion, if a
consensus could not be reached.
Data extraction and management
We developed data extraction forms using web-based software and
piloted these on a small selection of studies. NM and KSW, again
working independently, completed the data extraction form for
each included study. Agreements and disagreements were recorded
and resolved by discussion between Karla Soares-Weiser (KSW)
and NM. LP made a final decision if a consensus could not be
reached.
We extracted the following information on study characteristics:
number, age, gender and ethnicity of participants, co-morbid
disorders, duration of symptoms, use of medication, study aim,
clinical setting and country, who conducted the index test, cut-
off points used, type of scanner, MRI parameters, pre-processing
steps, covariates used in the General Linear Model, description of
the reference standard, whether any operational criteria or check-
lists were used, target condition, who conducted the reference
standard, description of the study process, and duration of follow-
up. We had also planned to record the number of true positive
(TP), true negative (TN), false positive (FP), and false negative
(FN) test results. If such data were not available, we planned to
derive them from summary statistics such as sensitivity, specificity,
and/or likelihood ratios, in order to construct a 2 x 2 table for
each study. However, none of the included studies had test accu-
racy data that we could extract, so instead we have reported their
findings narratively (see Findings).
Assessment of methodological quality
WeusedQUADAS-2 (Quality Assessment ofDiagnostic Accuracy
Studies), an updated version of the original QUADAS tool for the
assessment of quality in systematic reviews of diagnostic accuracy
studies (Whiting 2011). The QUADAS-2 tool is made up of four
domains: patient selection, index test, reference standard, and flow
and timing.We tailored the tool to our review, and which was used
to judge the risk of bias and applicability of included studies. Re-
view authors NM and KSW, working independently assessed the
included studies using a form that we piloted on a small selection
of studies. The inter-rater agreement was then measured and the
form adapted (see Appendix 2). It was then applied to the other
included studies. Any disagreements were resolved by consensus
with Clive E Adams (CEA) and Clare Davenport (CD).
We used the results of the quality assessment to describe the in-
ternal validity and external validity (applicability) of the included
studies. The results were also used to make recommendations for
the design of future studies. The use of overall quality scores for
individual studies is not recommended as the relative importance
of each quality domain is specific to each review topic. We, there-
fore, did not use QUADAS-2 other than to help the qualitative
commentary.
Statistical analysis and data synthesis
The primary objective for statistical analysis and data synthesis for
this review was to derive summary sensitivities and specificities
and corresponding 95% confidence regions from included stud-
ies. This would have been undertaken using either the hierarchical
summary ROC curve (HSROC) method (Rutter 2001), where
there was evidence of explicit or implicit threshold, or the hier-
archical bivariate model (Reitsma 2005), if included studies had
used the same threshold to classify participants as either test pos-
itive or test negative. However as we were unable to extract or
derive test accuracy data from included studies (TP, FP, TN, FN),
meta-analysis was not possible.
Investigations of heterogeneity
Planned investigations of heterogeneity using either hierarchical
modelling or subgroup analysis were not possible due to lack of test
accuracy data. The following variables are considered important
potential causes of heterogeneity that could not be investigated as
part of this review, but which may be relevant for updates of this
review or other reviews concerned with VBM for the diagnosis of
schizophrenia.
1. Participants
i) Age of onset: adolescents compared to adults.
Adolescence is a time where dynamic changes in the brain occur.
The interaction between the stage of brain development and
timing of first episode psychosis could confer heterogeneity when
comparing adolescent versus adult first episode psychosis
(Douaud 2007). Earlier onset of first episode psychosis has been
linked to a greater likelihood of exacerbated psychotic symptoms
following first episode (Gonzalez-Pinto 1998). Schizophrenia has
been shown to have an earlier onset of first episode psychosis
(adolescence and early adulthood) (McGrath 2008) in
comparison to first episode psychosis in bipolar disorder, which
typically occurs at a later stage (adulthood) (Gonzalez-Pinto
1998).
ii) Duration of untreated psychosis prior to first episode
diagnosis. It is thought that the longer the period of untreated
psychosis, the more progressed pathological changes in the brain
may be (Wyatt 1997).
6Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
iii) Medication: previously received, currently receiving,
and medication naive.
iv) Gender of participants. The mean age of onset for first
episode schizophrenia has been shown to be younger for men in
comparison to women (Larson 1996; Ochoa 2012).
2. Index test
i) MRI parameters: type of scanner, magnetic field
strength, image slice thickness-orientation-sequence, bandwidth,
and voxel dimensions.
ii) Pre-processing steps (spatial normalisation,
smoothing, modulation) (See Appendix 3).
iii) Use of covariates in the General Linear Model:
covariates relating to head or cranial size can be significant, due
to neurodevelopmental aberrations associated with schizophrenia
that can affect overall brain size and intracranial volume.
3. Reference standard
i) Reference standard used, e.g. ICD-9 or DSM-IV.
ii) Application of the reference standard, e.g. type of
medical professional, and individual medical professional,
algorithm or consensus decision.
4. Duration of follow-up between undergoing VBM and
schizophrenia diagnosis.
Sensitivity analyses
Had data been available for meta-analysis, we planned to use sen-
sitivity analyses to investigate the impact of study quality on over-
all diagnostic accuracy of VBM diagnoses. This strategy may be
relevant for updates of this review or other reviews concerned with
VBM for the diagnosis of schizophrenia.
Assessment of reporting bias
Standard funnel plots and tests for publication bias are likely to
be misleading for meta-analysis of test accuracy studies (Deeks
2005). We did not plan to assess publication bias.
R E S U L T S
Results of the search
We initially identified 405 potentially relevant references. After
removing 34 duplicate references, we excluded 280 references
through title and abstract screening. We assessed the full text of
the remaining 91 references, which resulted in 87 references being
excluded, mainly because they did not include participants with
first episode psychosis, did not include relevant comparisons for
our review, or the comparisons were with healthy controls (see
Characteristics of excluded studies for details of reasons for ex-
clusion). We included four studies (with five references), however
none of the studies provided the numbers or percentages of true
positives, false positives, true negatives and false negatives. See
Figure 1 for an overview of the selection process.
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Figure 1. Prisma Study flow diagram.
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Included studies
Study Design
Two studies were cross-sectional (Kubicki 2002; Morgan 2007)
and two were delayed verification (cohort) studies (de Castro-
Manglano 2011; Tordesillas-Gutierrez 2010). Two studies (de
Castro-Manglano 2011; Morgan 2007) recruited a consecutive
series of patients, and in the other two studies (Kubicki 2002;
Tordesillas-Gutierrez 2010), the method of enrolment was not
reported.
Setting
Kubicki 2002 was based in a hospital, de Castro-Manglano
2011 at an outpatient clinic, Morgan 2007 inpatient and out-
patient psychiatric services, and Tordesillas-Gutierrez 2010 did
not report the setting. Two studies were conducted in Spain (de
Castro-Manglano 2011; Tordesillas-Gutierrez 2010), one study in
the UK (Morgan 2007), and one in the USA (Kubicki 2002).
Participants
The included studies had a total of 275 participants (range from
28 to 118 participants), although only 251 were analysed in the
studies. All studies included participants with first episode psy-
chosis, howeverMorgan 2007 excluded participants with schizoaf-
fective disorder. Three studies reported the mean age of partici-
pants, which ranged from18.6 (standard deviation (SD) 4.9) years
to 27.1 (SD 7.6) years old; Tordesillas-Gutierrez 2010 did not re-
port on age. Two of the studies reported on the gender of partici-
pants and included both males and females (de Castro-Manglano
2011; Kubicki 2002). Duration of psychotic symptoms was re-
ported in two studies (de Castro-Manglano 2011; Morgan 2007),
which ranged from9.8 (SD18.2) weeks to 67.1 (SD124.9) weeks.
In addition to participants with first episode psychosis, all four
studies also included a healthy control group, which we did not
include for the purposes of this review.
Index Test
All studies used a magnetic field strength of 1.5 T. Two studies
(de Castro-Manglano 2011; Kubicki 2002) smoothed images us-
ing 12 mm isotropic Gaussian kernal and Tordesillas-Gutierrez
2010 used 5 mm FWHM. Pre-processing steps were clearly de-
scribed in de Castro-Manglano 2011 and Kubicki 2002; it was
unclear whetherMorgan 2007 carried out smoothing and normal-
isation; Tordesillas-Gutierrez 2010 used a specific pre-processing
algorithm (DARTEL), but the various optional processes chosen
to be employed are not reported. See Characteristics of included
studies for more details.
Reference standard
The reference standard in all studies was clinical diagnosis. In
Kubicki 2002, Morgan 2007 and Tordesillas-Gutierrez 2010 this
included the use of a clinical interview; medical records were
also used in de Castro-Manglano 2011 and Morgan 2007. Di-
agnoses were based on operational criteria in all studies (de
Castro-Manglano 2011, DSM-IV and ICD-10; Kubicki 2002,
DSM-III-R; Morgan 2007, ICD-10; Tordesillas-Gutierrez 2010,
DSM-IV).
Target Condition
The target condition was first episode schizophrenia in all stud-
ies. Morgan 2007 excluded patients with schizoaffective disor-
der, and Tordesillas-Gutierrez 2010 separated participants with
schizophreniform disorder from those with schizophrenia. The
other two studies did not report what was included in the defini-
tion of schizophrenia.
Excluded studies
We excluded 87 studies, themajority for more than one reason: 12
studies included participants with first episode psychosis, but only
compared them as a group with healthy controls, and a further
six included first episode schizophrenia compared with healthy
controls; 15 studies included participants with schizophrenia and/
or bipolar disorder, and again, compared these only with health
controls; 33 studies included participants with chronic psychosis,
or at-risk of psychosis; 12 studies did not make a relevant com-
parison as they were correlational studies, mostly with cognition;
five studies compared white matter only; three were meta-analyses
and one was a narrative review.
Awaiting assessment studies
There are no studies awaiting assessment.
Ongoing studies
We did not find any ongoing studies.
Methodological quality of included studies
See also Risk of bias and applicability concerns in Characteristics
of included studies, Figure 2 and Figure 3, for an overview of the
assessment of risk of bias and applicability concerns for each of
the four studies included in the review.
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Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Patient Selection
Two studies (de Castro-Manglano 2011; Morgan 2007), consec-
utively enrolled participants, and the other two studies were un-
clear about how participants were selected. In all studies par-
ticipants were undiagnosed at entry as they all included par-
ticipants with first episode psychosis. Kubicki 2002 and de
Castro-Manglano 2011 avoided inappropriate exclusions, it was
unclear in Tordesillas-Gutierrez 2010, andMorgan 2007 excluded
participants with schizoaffective disorder. Overall for patient se-
lection, two studies (de Castro-Manglano 2011; Kubicki 2002),
were considered to be at low risk of bias and the other studies two
were considered to be at unclear risk of bias. In terms of appli-
cability concerns regarding patient characteristics and setting, we
judgedMorgan 2007 to be of high concern as they included in the
schizophrenia group only patients meeting a narrow definition of
schizophrenia; the remaining studies were judged as low concern.
Index test
The index test results were interpreted without previous knowl-
edge of the reference standard results in de Castro-Manglano 2011
and Tordesillas-Gutierrez 2010; it was unclear in the other stud-
ies. The major focus of the four included studies was to locate the
brain regions withmaximum diagnostic differences. None of these
studies used a feature discrimination (or pattern classification) ap-
proach; consequently, there were no statistical cut-offs used to sep-
arate the patient groups. Pre-processing was clearly described in
both de Castro-Manglano 2011 and Kubicki 2002; it was unclear
in the other studies. It was unclear in all studies whether images
were inspected for motion artefacts. As a result, one study was
considered to be low risk of bias (de Castro-Manglano 2011) and
three studies at unclear risk of bias. All four studies were judged to
be of high applicability concern as VBM was not used to diagnose
schizophrenia, instead VBM was used to characterise grey matter.
Reference standard
In all studies the reference standard was described and would cor-
rectly classify schizophrenia, although it was unclear if the refer-
ence standard was interpreted without knowledge of the index test
result. As a result, for the reference standard domain, all studies
were considered to be of low risk of bias. In terms of applicability
concerns, all studies were judged as low concern.
Flow and timing
We considered all four studies to be of low concern for risk of bias
as in most studies all participants received a reference standard,
received the same reference standard, had an appropriate interval
between tests, and accounted for all of the participants in the
analysis.
Findings
The four included studies did not report data that we could use in
2 x 2 tables and meta-analysis. Instead we have summarised their
findings narratively:
de Castro-Manglano 2011
This study included 28 outpatients with first presentation of psy-
chosis who underwent a clinical assessment and scanning on entry
to the study. Patients were diagnosed according to the DSM-IV
and ICD-10 criteria after three years using all available clinical
information: 10 received a diagnosis of first episode schizophrenia
and 18 a diagnosis of first episode affective psychosis.
The study found no significant differences at the pre-specified sta-
tistical threshold, but a trend for the first episode affective psy-
chosis group to have less grey matter volume in the cerebellar ver-
mis than the first episode schizophrenia group in the VBM anal-
ysis (Talairach coordinates (x = -1, y = -45, z = -14); Z = 3.59; P
< 0.001 uncorrected).
The study also found that participants with a poor outcome after
three years, compared to those with a good outcome at three years,
had less grey matter volume in the right hippocampus (Talairach
coordinates x = 38, y = -11, z = -18; Z = 4.42; P < 0.001 uncor-
rected).
Kubicki 2002
This study recruited inpatients with first episode psychosis, who
were diagnosed based on their medical records and the Structured
Clinical Interview for DSM-III-R (SCID). Sixteen patients were
diagnosed with schizophrenia and 16 with affective disorder. The
majority of patients were scanned within three weeks of their ad-
mission to hospital, but four patients were scanned between nine
and 22 months after admission.
The same pattern of differences compared to healthy controls was
found bilaterally in the insula for patients with schizophrenia and
affective disorder, however, statistical differences were found be-
tween the groups of patients in the left superior temporal gyrus
and the left hippocampus, with patients with schizophrenia having
reduced grey matter density in these areas (Talairach coordinates,
Z score and P value not reported).
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Morgan 2007
Ninety-seven inpatients with first episode psychosis were included
in this study, but only 73 were analysed as some participants re-
fused consent and others were excluded by study investigators due
to participant motion, congenital hydrocephalus and subarach-
noid cyst. Participants were interviewed using the WHO Sched-
ules for Clinical Assessment in Neuropsychiatry (WHO-SCAN)
and received diagnoses based on the ICD-10. There were 44 pa-
tients with schizophrenia and 29with bipolar disorder or psychotic
depression.
When schizophrenia was compared with affective psychosis, con-
trolled for age and gender, no differences in total grey matter, cere-
brospinal fluid volume or ventricular volumes were found. When
total grey matter was added as a covariate, a deficit in regional
grey matter was found in the anterior cingulate gyrus, centred on
Brodmann’s Area in the affective psychosis group (Talairach coor-
dinates x = 1, y = -2, z = 36; Z score and P value not reported).
However, when type of antipsychotic was also added as a covariate,
no differences in regional grey matter were found.
Tordesillas-Gutierrez 2010
This study included118patientswith first episode psychosis. They
were diagnosedwith the SCID-I (StructuredClinical Interview for
Diagnosis) by an independent psychiatrist. Sixty-five patients were
diagnosed with schizophrenia, 32 with schizophreniform disorder
and 21 with non-schizophrenic non-affective psychosis.
No differences in grey matter were found between the
schizophrenic and schizophreniform patients. However, they did
find grey matter reductions in patients when compared to healthy
controls (Talairach coordinates andZ score not reported; P < 0.001
corrected), and these reductions were greater with greater severity
of disease.
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Summary of findings
What is the diagnostic accuracy of VBM for schizophrenia?
Patients/ population People with f irst episode psychosis
Prior testing Part icipants present ing for the f irst t ime at mental health services
Settings Inpat ients and outpat ients
Index test VBM
Importance Exploratory examinat ion of the diagnost ic ‘potent ial’ of VBM for use as an addit ional tool in the clinical examinat ion
of pat ients
Reference standard There is no gold standard for diagnosing schizophrenia. Reference standard used: clinical diagnosis using clinical
interview and/ or medical records, and based on DSM-III-R, DSM-IV and ICD-10 diagnoses
Studies Prospect ive studies including people with f irst episode psychosis (n = 4)
Test / subgroup Summary accuracy % (95%
CI)
No. of participants (stud-
ies)
Prevalence median (range) Implications Quality and comments
VBM Not applicable, see Quality
and comments
275 (4) See Quality and comments See Quality and com-
ments
No studies provided 2 x 2
data.
There were high applicability
concerns for all studies on
the index test domain as VBM
was not used to diagnose
schizophrenia, instead VBM
was used to characterise grey
matter
CAUTION: The results on this table should not be interpreted in isolation from the results of the individual included studies. These are reported in the main body of the text
of the review.
ICD: Internat ional Stat ist ical Classif icat ion of Diseases and Related Health Problems
DSM: Diagnost ic and Stat ist ical Manual of Mental Disorders
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D I S C U S S I O N
Summary of main results
This systematic review includes four studies that measure differ-
ences in grey matter using voxel-based morphometry (VBM) in
patients with psychosis. The studies included participants with
first episode psychosis, but did not use VBM to diagnose the par-
ticipants. The included studies had a total of 275 participants and
251 were analysed. The reference standard in all studies was clin-
ical diagnosis including the use of operational criteria.
The quality assessments of the studies were mostly rated as having
low and unclear risk of bias. There were high applicability con-
cerns for all studies on the index test domain as VBM was not
used to diagnose schizophrenia, rather VBM was used to quantify
the magnitude of differences in grey matter volume. None of the
included studies reported data that could be used in the analysis.
There are no data on the diagnostic accuracy of VBM for diag-
nosing schizophrenia.
Summary of findings gives information on the quality and appli-
cability of evidence.
Strengths and weaknesses of included studies
We did not find any studies that assessed the diagnostic accuracy
of VBM for schizophrenia in participants with first episode psy-
chosis. The four studies we were able to identify included people
with first episode psychosis, who were scanned and were assessed
with a relevant reference standard, but the studies were not de-
signed to use VBM to diagnose participants, instead they identi-
fied differences in grey matter distribution in brain regions.
Patient selection was unclear in Morgan 2007 and Tordesillas-
Gutierrez 2010 as the study authors did not report the methods
used to select participants. The risk of bias in the index test domain
was unclear in all studies except de Castro-Manglano 2011 as
blinding of the reference standard results was not reported and
the pre-processing steps used were not always fully reported. The
reference standard was well described in most studies andmatched
the inclusion criteria of the review. All studies were conducted in
a research setting, rather than clinical setting.
Strengths and weaknesses of the review
We tried to identify all relevant studies in our search strategy, and
we did not apply any restrictions based on language or type of
document in the search. However, it is possible that we were not
able to identify some studies.
We found that the completion of QUADAS 2 involved much
discussion between review authors, and needed to adapt the sig-
nalling questions multiple times before we reached agreement.We
see this process as a strength of the review, designed to mitigate
against bias.
Previous research
We know of no other reviews testing the diagnostic accuracy of
VBM for schizophrenia.
Applicability of findings to the review question
An important issue with respect to the applicability of VBM stud-
ies to the question of this review is that almost all studies were prin-
cipally aimed at ‘localising’ grey matter changes, rather than es-
tablishing the accuracy of VBM per se in separating the diagnostic
groups. As a result, the statistical approaches applied were aligned
to the goal of discovering continuous differences in grey matter
distribution, rather than establishing the utility of distributed, al-
beit low effect-size differences, in diagnosing schizophrenia during
first presentation.
In recent times, reports on explicit attempts to test the useful-
ness of VBM approach to diagnose schizophrenia are emerging
(for example, Schnack 2014 and Iwabuchi 2013). Unfortunately,
to date most of these studies focus on separating people with
schizophrenia from healthy individuals, rather than from those
with non-schizophreniform but psychotic disorders. Also, none of
these studies have tackled the issue of diagnostic utility for first
episode psychosis. Our present review highlights the gap in this
area of research.
Schnack 2014, however, did measure the diagnostic accuracy of
VBM with the addition of support vector machine modelling to
separate participants with schizophrenia and bipolar disorder, al-
though this was in a chronically ill sample of patients. In this
study they used scans from a discovery sample of participants with
schizophrenia and bipolar disorder to train support vector ma-
chine to build models to separate patients with schizophrenia from
bipolar patients, based on their grey matter densities. These mod-
els were then tested by applying them to the data of the validation
sample of participants. A post hoc analysis was done, recalculat-
ing the diagnostic accuracy with the participants’ gender weighted
according to the discovery sample. When the participants’ scans
were applied to the discovery sample’s model, the test sensitivity
was 48% and the specificity was 79%. When the classification
thresholds were adjusted after the ROC curve analysis, the sensi-
tivity was 55% and the specificity was 63%.When the analysis was
re-weighted by gender, the sensitivity was 71% and the specificity
was 65%. The model was thus developed in the same sample it
was then tested on. Further research of this kind in investigating
the potential of VBM for diagnosing schizophrenia needs to be
undertaken mindful of this limitation.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
There is no evidence to currently support diagnosing schizophre-
nia (as opposed to other psychotic disorders) using the pattern of
brain changes seen in voxel-based morphometry (VBM) studies
in patients with first episode psychosis. The lack of clinical appli-
cability of VBM studies conducted so far significantly limits their
utility for diagnostic purposes.
Implications for research
VBM studies are largely focused on locating the distribution of
the most prominent structural changes in schizophrenia, rather
than estimating how the presence of structural changes can assist
in clinical diagnostic decisions per se. Studies with an emphasis
on statistical discrimination approaches, using all of the brain-
wide information collected from VBM studies, especially in first
episode populations with prospective diagnostic validation, need
to be conducted to realise the diagnostic potential of VBM. We
also note a wide variation in the reporting of the image processing
approaches, use of multiple test corrections and quality of clinical
case ascertainment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Castro-Manglano 2011
Study characteristics
Patient sampling Prospective and consecutive: “consecutive series of patients...presenting for the first time with a
psychotic episode at the outpatient clinic”
Patient characteristics and set-
ting
N of participants: 28.
N analysed: 28.
Age: mean age 18.6 years (SD 4.9).
Gender: 17 M, 11 F.
Ethnicity: Caucasian.
Comorbid disorders: not reported.
Duration of symptoms: 9.8 weeks (SD 18.2).
Concurrent medications used: 22/28 of the participants (olanzapine, n = 11; risperidone, n = 8;
ziprasidone, n = 4; aripiprazole, n = 1; haloperidol plus clozapine and olanzapine, n = 2) mood
stabilisers (n = 9) or antidepressants (n = 15).
Inclusion criteria: first presentation of symptoms meeting criteria for a non-medical, non-toxic
psychosis [InternationalClassificationofDiseases (ICD)-10: F20 schizophrenia and F30-39 affective
disorders-psychotic coding; World Health Organization and DSM-IV classification]; age at first
evaluation between 11 and 29 years old.
Exclusions criteria: presence of a concomitant Axis I disorder; alcohol or other substance abuse; a
significant neurological or medical illness, or a history of head trauma resulting in loss of conscious-
ness for over one hour; previous psychotic episode; substance-induced psychotic symptoms (ICD-
10: F10) (25); being unable to complete or to perform some of the different evaluations included
in the protocol
Study aim: “to examine regional GM volume in adolescents and young adults with a first episode of
psychosis, and, within this sample, to compare patients with affective psychoses and schizophrenia.
A second objective was to assess the extent to which volumetric MRI measures at first presentation
(in the whole sample) predicted subsequent clinical outcome”
Clinical setting: outpatients.
Country: Spain.
Index tests Test conducted by: not reported.
Cut-off points used: not reported.
Type of scanner: 1.5 Tesla Siemens SymphonyMaestro Class Imaging System (Erlangen,Germany)
MRI parameters
“The voxel dimensions were 1.0 x 1.0 x 1.5 mm3; matrix size 256 x 256; field of view (FOV): 256
x 256 mm2; band width 230 Hz pixel; time-to-repetition (TR): 1,810 msec; time-to-echo (TE):
2.39 msec, inversion time 1.1 msec; flip angle 20; echo time 4.6 msec; slice thickness 2 mm.”
Pre-processing steps
• Spatial normalisation: “Images were segmented and then normalized to an asymmetric T1-
weighted template in Montreal Neurological Institute (MNI) stereotactic space, in a recursive
fashion.”
• Optimised: “Images were preprocessed using optimised voxel-based morphometry (VBM)”
• Smoothing: 12 mm isotropic Gaussian kernel
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de Castro-Manglano 2011 (Continued)
• Modulation: “This modulation step involves multiplying the spatially normalized GM by its
relative volume before and after spatial normalization.”
Use of covariates in the General Linear Model: age, gender and total grey matter
Target condition and reference
standard(s)
Reference standard: “Diagnoses were made on the basis of all the clinical information available at
follow-up, according to the ICD-10 and DSM-IV criteria.”
Operational criteria used: DSM-IV and ICD-10.
Target condition: schizophrenia, first episode.
Conducted by: not reported.
Flow and timing Study process: At baseline, all subjects were scanned and had a clinical assessment. The clinical
assessment was repeated three years later, and included a clinical interview using various scales (K-
SADS-PL, PANSS, HDRS, CGI, DSM-IV (GAF). Diagnoses were made on the basis of all the
clinical information available at follow-up, according to the ICD-10 and DSM-IV criteria
Follow up: 3 years, follow-up data were obtained from 22 (79%) of the 28 patients: two had died
from suicide during the follow-up period, and 4 declined to be re-assessed
Comparative
Notes Also included a healthy control group, which we did not consider for this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Were participants undiagnosed
at entry to study?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Did the study pre-specify cut-
offs for VBM?
No
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de Castro-Manglano 2011 (Continued)
Was imaging pre-processing
carried out?
Yes
Were images inspected for mo-
tion artefacts?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive a refer-
ence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Were missing or uninter-
pretable results reported?
Yes
Low
Kubicki 2002
Study characteristics
Patient sampling Prospective, not reported if consecutive: “Patients who were entering the hospital for the first time
with psychosis or were being transferred or readmitted within 8 months of the first hospitalisation
for psychosis were recruited.”
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Kubicki 2002 (Continued)
Patient characteristics and set-
ting
N of participants: 32.
N analysed: 32.
Age: 26 years (SD 7.5) schizophrenic group; 23.7 (SD 4) years affective psychosis group.
Gender: 27 M, 5 F.
Ethnicity: not reported.
Comorbid disorders: not reported.
Duration of symptoms: not reported.
Concurrent medications used: not reported. The median duration of treatment with any psy-
chotropic medication before scanning was 1.7 months for the schizophrenic patients and 0 months
for the patients with affective disorder
Inclusion criteria: age 18 to 55 years; INQ above 75; right-handedness; no lifetime history of
alcohol or drug dependence.
Exclusions criteria: history of seizures, head trauma with loss of consciousness, and neurological
disorder
Study aim: To evaluate VBM as a more efficient and complete method than ROI (regions of
interest) for characterisation of greymatter abnormalities in patientswith first-episode schizophrenia.
Secondary aim was to compare and validate VBM with ROI analysis by using patients who had
been previously investigated using ROI methodology
Clinical setting: inpatients.
Country: USA.
Index tests Test conducted by: not reported.
Cut-off points used: not reported.
Type of scanner: 1.5-T General Electric scanner (GE Medical Systems, Milwaukee)
MRI parameters
“A series of 124 contiguous coronal imageswere acquired using anSPGRsequencewith the following
parameters: TR, 35 ms; TE, 5 ms; 45° flip angle; 24-cm field of view; NEX, 1.0 (number of
excitations); matrix, 256 x 256 (192 phase-encoding steps). The voxel (volume of pixel) dimensions
were 0.9375 x 0.9375 x 1.5 mm.”
Pre-processing steps
• Spatial normalisation: “spatial normalization of all images to the same high spatial resolution
stereotactic space (1-mm isotropic voxels, SPM 99 T1-weighted template image).”
• Standardised: “Each of the subjects’ images was registered to the same template image by
minimizing the residual sum of squared differences between them.”
• Smoothing: 12 mm isotropic Gaussian kernel
• Modulation: not reported
Use of covariates in the General Linear Model: global grey matter intensity (global normalisation)
Target condition and reference
standard(s)
Reference standard: “Diagnoses were based on the Structured Clinical Interview for DSM-III-R
(SCID), review of hospital course, and medical records.”
Operational criteria used: DSM-III-R.
Target condition: schizophrenia, first episode.
Conducted by: not reported.
Flow and timing Study process:Diagnoses were based on the Structured Clinical Interview for DSM-III-R (SCID)
, review of hospital course, and medical records. Patients were scanned using MRI, these scans were
analysed previously using ROI and were re-analysed using VBM. “Of the 33 patients scanned, 29
received an MRI within 3 weeks of entering McLean Hospital, and the remaining four (two with
schizophrenia, two with affective disorder) returned after discharge for imaging (15 and 22 months
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for schizophrenia, respectively, and 9 and 18 months for affective disorder).”
Follow up: three weeks to 22 months.
Comparative
Notes Also included a healthy control group, which we did not consider for this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
Were participants undiagnosed
at entry to study?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Did the study pre-specify cut-
offs for VBM?
No
Was imaging pre-processing
carried out?
Yes
Were images inspected for mo-
tion artefacts?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive a refer-
ence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Were missing or uninter-
pretable results reported?
Yes
Low
Morgan 2007
Study characteristics
Patient sampling Prospective and consecutive: patients “presenting consecutively for the first time to local psychiatric
services (in-patient and outpatient) between 1997 and 2000 with symptoms meeting functional
psychosis”.
“Only patientsmeeting criteria for a narrowdefinition of schizophrenia (ICD-10F20)were included
in the ‘schizophrenia’ group. Patients diagnosed with bipolar disorder or depressive psychosis were
allocated to the ‘affective psychosis’ group (ICD-10 F30-39). To ensure the diagnostic homogeneity
of the two groups, patients with schizoaffective disorder were excluded from either group.”
Patient characteristics and set-
ting
N of participants: 97.
N analysed: 73.
Age: mean age 27.1 years (SD 7.6).
Gender: not reported.
Ethnicity: white British patients 27 (37%), other ethnicities not reported.
Comorbid disorders: not reported.
Duration of symptoms: see notes.
Concurrent medications used: Not reported.
Inclusion criteria: age 16-65 years; resident in defined area; presenting consecutively for the first
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time to local psychiatric services (in-patient and outpatient) between 1997 and 2000 with symptoms
meeting functional psychosis criteria (ICD-10: F20 Schizophrenia and F30-39 Affective disorders
- psychotic codings; World Health Organization, 1992).
Exclusions criteria: head trauma history with 41-hour unconsciousness; central nervous system
disease; poor English fluency; transient psychotic symptoms resulting from acute intoxication (ICD-
10) following consumption of psychoactive substance
Study aim: To determine which brain abnormalities are specific to schizophrenia and affective
psychosis
Clinical setting: inpatients and outpatients.
Country: UK.
Index tests Test conducted by: not reported.
Cut-off points used: not reported.
Type of scanner: GE Signa 1.5-T system
MRI parameters
“Contiguous, interleaved proton-density and T2-weighted 3mm thick coronal plane dual-echo
images were acquired, providing whole brain coverage. A repetition time of 4000ms and effective
echo times of 20ms and 85ms were used with 8-echo train length.Matrix size was 256x192, collected
from a rectangular field-of-view of 22 cm x 616.5 cm, giving an in-plane resolution of 0.859mm.
Total acquisition time was 10min, 12s.”
Pre-processing steps
• Spatial normalisation: Segmentation using a fuzzy-clustering algorithm, followed by group
template-based registration. Details of normalisation not reported.
• Optimised: not optimised.
• Smoothing: not reported.
• Modulation: not modulated.
Use of covariates in the General Linear Model: not reported.
Target condition and reference
standard(s)
Reference standard: “Patients were interviewed using theWHO Schedules for Clinical Assessment
in Neuropsychiatry (WHO-SCAN). ICD-10 diagnoses were made in consensus meetings with
senior clinicians, using WHO-SCAN information and clinical notes.”
Operational criteria used: ICD-10.
Target condition: schizophrenia, first episode.
Conducted by: senior clinicians.
Flow and timing Study process: “Patients were interviewed using the WHO Schedules for Clinical Assessment
in Neuropsychiatry (WHO-SCAN) (World Health Organization, 1994). ICD-10 diagnoses were
made in consensus meetings with senior clinicians using WHO-SCAN information and notes.”
Scans were acquired, timing not reported.
“9 [patients] did not complete the full scanning procedure and therefore were not included in
the analysis. Fifteen further scans were excluded due to (a) subject motion n=13; (b) congenital
hydrocephalus n=1; (c) subarachnoid cyst n=1.”
Follow up: not reported.
Comparative
Notes Also included a healthy control group, which we did not consider for this review
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Were participants undiagnosed
at entry to study?
Yes
Unclear High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Did the study pre-specify cut-
offs for VBM?
No
Was imaging pre-processing
carried out?
Unclear
Were images inspected for mo-
tion artefacts?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive a refer-
ence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Were missing or uninter-
pretable results reported?
Yes
Low
Tordesillas-Gutierrez 2010
Study characteristics
Patient sampling Prospective, not reported if consecutive: “sample (118) of first episode psychosis patients”
Patient characteristics and set-
ting
N of participants: 118.
N analysed: 118.
Age: not reported.
Gender: not reported.
Ethnicity: not reported.
Comorbid disorders: not reported.
Duration of symptoms: not reported.
Concurrent medications used: not reported.
Inclusion criteria: first episode psychosis patients.
Exclusions criteria: not reported.
Study aim: to study whether there is a tendency towards reduction in grey matter in schizophrenia
patients, and to analyse the differences between schizophrenia and schizophreniform disorders
Clinical setting: not reported.
Country: Spain.
Index tests Test conducted by: not reported.
Cut-off points used: not reported.
Type of scanner: 1.5 T GE scanner
MRI parameters
“All MRI were acquired in a 1.5 T GE scanner; SPGR sequence (TE=5 ms, TR=24 ms, slice
thickness=1.5 mm).”
Pre-processing steps
• Spatial normalisation: DARTEL (Diffeomorphic Anatomical Registration Through
Exponentiated Lie Algebra) procedures were used, parameters unspecified.
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Tordesillas-Gutierrez 2010 (Continued)
• Optimised: DARTEL procedures were used where optimisation is the default pre-processing
option. But the details of this procedure are not reported.
• Smoothing: isotropic Gaussian kernel of 5 mm FWHM.
• Modulation: DARTEL procedures were used, parameters unspecified.
Use of covariates in the General Linear Model: age, gender and intracranial volume
Target condition and reference
standard(s)
Reference standard: “an independent psychiatrist confirmed diagnosis using the SCID-I.”
Operational criteria used: DSM-IV.
Target condition: schizophrenia, first episode.
Conducted by: psychiatrist.
Flow and timing Study process: 118 patients with a first episode psychosis underwent an MRI scan in the first weeks
of inclusion in the PAFIP program. At 6months of inclusion an independent psychiatrist confirmed
diagnosis using the SCID-I
Follow up: 6 months.
Comparative
Notes Also included a healthy control group, which we did not consider for this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Were participants undiagnosed
at entry to study?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Did the study pre-specify cut-
offs for VBM?
No
Was imaging pre-processing
carried out?
Unclear
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Were images inspected for mo-
tion artefacts?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive a refer-
ence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Were missing or uninter-
pretable results reported?
Yes
Low
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ananth 2002 Participants with schizophrenia compared to healthy controls
Bangalore 2008 Participants with first episode schizophrenia compared to healthy controls
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Bangalore 2009 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
Benedetti 2010 Participants with chronic schizophrenia.
Berge 2011 Participants with first episode psychosis compared to healthy controls
Bodnar 2012 Participants with first episode schizophrenia only.
Borgwardt 2010 Participants with first episode psychosis compared to people with an at-risk mental state and healthy
controls
Borgwardt 2010a Participants with first episode psychosis compared to people with an at-risk mental state and healthy
controls
Brown 2011 Participants with chronic schizophrenia and bipolar disorder
Cascella 2010 Participants with schizophrenia compared to healthy controls
Chaim 2010 Participants with first episode psychosis compared to healthy controls
Chow 2011 Participants with 22q11.2 deletion syndrome, psychotic and non-psychotic subgroups compared
Chua 2007 Participants with first episode psychosis compared to healthy controls
Colombo 2012 Participants with first episode psychosis.
Only white matter structure compared.
Cui 2010 Participants with chronic schizophrenia and bipolar disorder
Cui 2011 Participants with chronic schizophrenia and bipolar disorder
Dazzan 2012 Participants at ultra-high risk of schizophrenia.
de Castro-Manglano 2011b Participants with first episode psychosis.
Measured longitudinal changes, not cross-sectional group comparisons
Deng 2011 Participants with first episode psychosis compared to healthy controls
Douaud 2009 Participants with schizophrenia compared to healthy controls
Eack 2010 Participants with early stage schizophrenia or schizoaffective disorder, no comparison between diag-
nostic groups (randomised control trial testing cognitive enhancement therapy versus enriched support
therapy)
Ellison-Wright 2010 Meta-analysis.
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Fornito 2009 Meta-analysis.
Heuser 2011 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
Horacek 2010 Participants with schizophrenia compared to healthy controls
Huang 2009 Participants with first episode psychosis compared to healthy controls
Hulshoff 2001 Participants with schizophrenia compared to healthy controls
Ivleva 2012 Participants with chronic psychosis.
James 2011 Participants with adolescent onset schizophrenia compared to healthy controls
Janssen 2008 Participants with first episode psychosis compared with healthy controls
Janssen 2009 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
Job 2003 Participants with first episode schizophrenia compared to people at high risk of schizophrenia and
healthy controls
Job 2005 Participants at high risk of schizophrenia compared to healthy controls
Kawasaki 2004 Participants with chronic schizophrenia or schizotypal disorder
Lebedev 2010 Participants with depression.
Lu 2011 Participants with first episode psychosis. Only white matter structure compared using diffusion tensor
imaging
Lui 2009 Participants with first episode schizophrenia compared with healthy controls
Lui 2009a Participants with first episode schizophrenia compared with healthy controls
Malchow 2010 Participants with first episode schizophrenia only.
Malla 2011 Participants with first episode psychosis, no comparison with between diagnostic groups (compares
length of duration of undiagnosed psychosis)
Mane 2009 Participants with first episode psychosis compared with healthy controls
Maric 2003 Participants with schizophrenia compared to healthy controls
McIntosh 2004 Participants with schizophrenia, bipolar disorder and at high risk compared to healthy controls
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McIntosh 2006 Participants with schizophrenia, bipolar disorder and at high risk compared to healthy controls
McIntosh 2009 Participants with schizophrenia, bipolar disorder and at high risk compared to healthy controls
Meda 2008 Participants with schizophrenia (first episode and chronic) compared to healthy controls
Meijer 2009 Participants at ultra-high risk for psychosis.
Meijer 2010 Participants at ultra-high risk for psychosis.
Meijer 2011 Participants at ultra-high risk for psychosis.
Melonakos 2011 Meta-analysis.
Minatogawa-Chang 2009 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
Modinos 2009 Participants with schizophrenia only.
Molina 2010 Participants with schizophrenia only.
Molina 2010a Participants with first episode psychosis compared to healthy controls
Molina 2010b Participants with chronic schizophrenia and bipolar disorder
Molina 2011 Participants with chronic schizophrenia and bipolar disorder
Moorhead 2004 Participants with schizophrenia (with and without comorbid learning disability), people with learning
disability and health controls
Mouchet-Mages 2011 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
Nenadic 2010 Participants with schizophrenia only.
Palaniyappan 2011 Participants with chronic psychosis.
Perez-Iglesias 2010 Participants with first episode psychosis. Only white matter structure compared
Potvin 2007 Participants with schizophrenia (with and without substance abuse disorders) compared to healthy
controls
Roman-Urrestarazu 2011 Participants at clinical risk, family risk and healthy controls
Rosa 2012 Participants with first episode psychosis, no comparison between diagnostic groups (correlation study
with cognition)
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Ruef 2012 Participants with first episode psychosis compared to healthy controls
Rund 2004 Participants with chronic schizophrenia and depression.
Salgado-Pineda 2004 Narrative review.
Salgado-Pineda 2011 Schizophrenia compared to healthy controls only.
Schiffer 2010 Participants with chronic schizophrenia.
Schiffer 2010a Participants with schizophrenia, with and without comorbid substance abuse
Schiffer 2010b Participants with schizophrenia compared to healthy controls
Schnack 2014 Participants with chronic schizophrenia, bipolar disorder and healthy controls
Segall 2009 Participants with schizophrenia (first episode and chronic) compared to healthy controls
Situ 2010 Participants with schizophrenia compared to healthy controls
Stanfield 2009 Participants with bipolar disorder compared to healthy controls
Sussmann 2009 Participants with schizophrenia and bipolar disorder. Only white matter structure compared
Suzuki 2010 Participants with first episode schizophrenia compared to healthy controls
Tandon 2012 Adolescent relatives of schizophrenic patients and healthy controls
Trost 2011 Participans with schizophrenia, bipolar disorder, obsessive compulsive disorder and healthy controls
Walter 2012 Participants with an at-risk mental state.
Wang 2009 Participants with schizophrenia compared to healthy controls
Watson 2012 Participants with first episode psychosis compared to healthy controls
Witthaus 2008 Participants with first episode schizophrenia, ultra-high risk for schizophrenia and healthy controls.
Only white matter structure compared
Witthaus 2009 Participants with first episode schizophrenia, ultra-high risk for schizophrenia and healthy controls
Wojtalik 2013 Participants with early course schizophrenia, no comparison between diagnostic groups (correlation
study with emotional intelligence)
Yüksel 2010 Participants with schizophrenia, bipolar disorder and healthy controls. Not first episode
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Yüksel 2012 Participants with schizophrenia, bipolar disorder and healthy controls. Not first episode
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D A T A
This review has no data.
A P P E N D I C E S
Appendix 1. Search strategies
Database Phase and date Search strategy
MEDLINE
(OvidSP)
Dates:1946 to
2013
Phase I Date:
08-05-12
Phase II Date:
06-12-13
1 voxel-based morphometry.tw. (1593)
2 VBM.tw. (883)
3 1 or 2 (1785)
4 exp Schizophrenia/ (77987)
5 schizophren$.tw. (76507)
6 4 or 5 (95672)
7 3 and 6 (220)
EMBASE
(OvidSP)
Dates: 1980 to
2013
Phase I Date:
08-05-12
Phase II Date:
06-12-13
1 voxel-based morphometry.tw. (2318)
2 VBM.tw. (1419)
3 1 or 2 (2635)
4 exp Schizophrenia/ (119513)
5 schizophren$.tw. (99363)
6 4 or 5 (131921)
7 3 and 6 (345)
PsycINFO
(OvidSP)
Dates:1806 to
2013
Phase I Date:
08-05-12
Phase II Date:
06-12-13
1 voxel-based morphometry.tw. (1167)
2 VBM.tw. (528)
3 1 or 2 (1223)
4 exp Schizophrenia/ (65558)
5 schizophren$.tw. (89948)
6 4 or 5 (90931)
7 3 and 6 (199)
All databases searched from inception.
All searches were undertaken, added to a common database and duplicates deleted
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Appendix 2. QUADAS-2
DOMAIN 1: PATIENT SELECTION
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1. Was a consecutive or random sample of patients enrolled?
‘Yes’ if a random sample of patients with suspected psychotic symptoms were included, or con-
secutive patients were enrolled
‘No’ if the patients were specifically selected (not random sample) to be included in the study
‘Unclear’ if insufficient information is provided
2. Were participants undiagnosed at study entry?
‘Yes’ if participants did not have a specific diagnosis at entry to the study even if they had
psychotic symptoms.
‘No’ if participants had a specific diagnosis at entry to the study.
‘Unclear’ if insufficient information is provided
3. Did the study avoid inappropriate exclusions?
‘Yes’ if the study explicitly states that there were no exclusions or there were no inappropriate
exclusions
‘No’ if some patients were inappropriately excluded e.g. if they were deemed “difficult-to-diag-
nose” patients
‘Unclear’ if exclusions were not explicitly reported in the study
Applicability
Are there concerns that the included patients and setting do not match the review question?
‘No’ if included patients were those with psychosis but not a specific diagnosis
‘Yes’ if patients already had a specific diagnosis upon entry to study (e.g. inclusion criteria lists specific diagnoses)
’Unclear’ Not enough information to decide
DOMAIN 2: INDEX TEST
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signalling question 1. Were the index test results interpreted without knowledge of the results of the reference
standard?
‘Yes’ if the index test was conducted before the reference standard, or if the person applying the
index test was blinded to the results of the reference standard
‘No’ if the index test operator knew the results of the reference standard
‘Unclear’ if insufficient information is provided
2. Did the study pre-specify cut-offs for VBM?
’Yes’ if the study stated the VBM threshold needed to be present to diagnose schizophrenia
‘No’ if the study does not state theVBM threshold they considered necessary to diagnose schizophre-
nia
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(Continued)
3. Was image pre-processing carried out?
’Yes’ if the method of image pre-processing was clearly stated and the same for all participants
‘No’ if image pre-processing was not uniformly carried out for all participants
‘Unclear’ if insufficient information is provided
4. Were images inspected for motion artefacts?
’Yes’ if images were inspected for motion artefacts for all participants using prespecified criteria
‘No’ if motion artefact inspection was not uniformly carried out for all participants
‘Unclear’ if insufficient information is provided
Applicability
Are there concerns that the index test, its conduct, or interpretation, differ from the review question?
’Yes’ VBM is not being applied to differentiate early stage schizophrenia disorder from other forms of psychosis
’No’ VBM is being applied to differentiate early stage schizophrenia from other forms of psychosis
DOMAIN 3: REFERENCE STANDARD
Risk of bias: Could the reference standard, its conduct or interpretation have introduced bias?
Signalling question 1. Is the reference standard likely to correctly classify the target condition?
‘Yes’ if the history and clinical examination is conducted by a qualified professional (psychiatrist,
nurse, social worker)
‘No’ if the history and clinical examination is conducted by insufficiently qualified individuals
‘Unclear’ if insufficient information is provided
2. Were the reference standard results interpreted without knowledge of the results of the
index test?
‘Yes’ if the reference standard was conducted before the index test, or if the person applying the
reference standard was blinded to the results of the index test
‘No’ if the reference standard operator knew the results of the index test
‘Unclear’ if insufficient information is provided
Applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?
‘No’ the paper specifically looks at diagnosing early stage schizophrenia
‘Yes’ if the paper also includes schizophrenia-like illnesses
‘Unclear’ if insufficient information is provided
DOMAIN 4: FLOW AND TIMING
Risk of Bias: Could the patient flow have introduced bias?
Signalling question 1. Was there an appropriate interval between index test and reference standard?
’Yes’ if reference standard and index text were applied within 4 weeks
’No’ if reference standard or index test were applied beyond 4 weeks between them
’Unclear’ if not enough information is given to assess whether there was an appropriate interval
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(Continued)
2. Did all patients receive a reference standard?
’Yes’ if all patients had details of history and clinical examination, with or without operational
criteria
‘No’ if not all patients had a description of history and clinical examination with or without
operational criteria
‘Unclear’ if insufficient information is provided
3. Did all patients receive the same reference standard?
‘Yes’ if all patients were diagnosed with the same operational criteria that were applied to all
patients, and that received the same clinical follow up
‘No’ if all patients received history and clinical examination but only some received operational
criteria, or different operational criteria
‘Unclear’ if insufficient information is provided
4. Were all patients included in the analysis?
’Yes’ if there are no patients excluded from the analysis
’No’ if there are patients excluded from the analysis
’Unclear’ if not enough information is given to assess whether any patients were excluded from
the analysis
5. Were missing or uninterpretable results reported?
’Yes’ if there were no missing or uninterpretable results, or they were adequately reported
’No’ if missing and uninterpretable results were not adequately reported
’Unclear’ if there was no information about missing or uninterpretable results
Appendix 3. Pre-processing steps (spatial normalisation, smoothing, modulation)
Normalisation Images are spatially normalized so that they are in the same stereotactic
space (a precisemapping systemusing3-Dcoordinates) and registered
to the same template image. This allows for the combination of data
across individuals and comparison of different studies. Heterogeneity
will arise if studies do not all report results in the form of coordinates
within a common stereotactic space (of which ’Talairach space’ is
most commonly used) (Huettel 2009).
Optimised versus standardised voxel-based morphometry ‘Optimised voxel-based morphometry’ (where images are first sepa-
rated into grey matter, white matter and cerebrospinal fluid before
being registered to a template) can reduce the misinterpretation of
significant differences in comparison to ‘standard voxel-based mor-
phometry (where images are first registered to the template and then
separated) (Mechelli 2005). Comparisons of studies that use different
methods can distort results
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Smoothing This makes the data more normally distributed and reduces the
variance across subjects (Whitwell 2009). However, the Gaussian
smoothing kernels that are used can vary in size from 0-16 mmwhich
can produce heterogeneity (Jones 2005).
Modulation Spatial normalization requires the warping of brain regions to fit the
same sterotactic space. Modulation can be used to compensate for
this warping process by providing a relative volume for each voxel
in contrast to unmodulated parameters which give data about con-
centration (Segall 2009). Heterogeneity can arise if some studies use
modulation and others do not
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